Your browser version is outdated. We recommend that you update your browser to the latest version.

Cancer Treatment 

Cancer is the leading cause of death worldwide, accounting for more than 8 million deaths annually, and this number is projected to continue rising, with an estimated 13 million deaths in 2030. In the western world one out of three will get cancer during their lifetime, and more than one third of these patients will die from their disease. During the last decade, the 5 year survival has improved markedly for most cancers, and today there is more than 80 % chance of surviving breast, ovarian, prostate and colon cancer.

The most efficient treatment of cancer today is surgery, but often the tumor is localized to in-operable sites or has spread to distant sites called metastasis. Other treatment types includes radiotherapy, chemotherapy or therapeutic antibodies.

A major improvement in cancer treatment for the last 5 years has been the approval of immune checkpoint inhibitors (ICI) that prevent the tumor from suppressing the immune system once it attacks the tumor. The ICIs have demonstrated good effect in certain patients, but it is clear that to improve patient outcome even further, additional combination treatment is warranted.

The technology by MonTa Biosciences is a type of immunotherapy to complement both ICI treatment, but also a number of other treatments approved today.